NPS Pharmaceuticals to Report First Quarter 2013 Financial Results Business Wire BEDMINSTER, N.J. -- May 01, 2013 NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its first quarter 2013 financial results on Thursday, May 9, 2013 at approximately 8:00 a.m. ET. The press release will be followed by a conference call and webcast at 8:30 a.m. ET. To participate in the conference call, dial (866) 515-2910 and use passcode 73536235. International callers may dial (617) 399-5124, using the same passcode. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the investors’ calendar of events page on the NPS website at http://www.npsp.com/calendar. If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 47948306 until midnight ET, May 23, 2013. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available through the NPS website for the same period. About NPS Pharmaceuticals NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (U.S.)/Revestive® (EU) 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection is approved for adult short bowel syndrome (SBS). NPS is also developing Natpara® (rhPTH[1-84]) for the treatment of adult hypoparathyroidism and, subject to the resolution of certain manufacturing issues, expects to submit its Biologic License Application (BLA) to the FDA in 2013. NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals and Kyowa Hakko Kirin. Contact: NPS Pharmaceuticals, Inc. Gail Brophy, 908-450-5335
Bank of Japan Keeps Plan for 80T Yen Annual Rise in Monetary Base
NPS Pharmaceuticals to Report First Quarter 2013 Financial Results
Press spacebar to pause and continue. Press esc to stop.